283 related articles for article (PubMed ID: 34994805)
1. Metabolic, structural and biochemical changes in diabetes and the development of heart failure.
Ho KL; Karwi QG; Connolly D; Pherwani S; Ketema EB; Ussher JR; Lopaschuk GD
Diabetologia; 2022 Mar; 65(3):411-423. PubMed ID: 34994805
[TBL] [Abstract][Full Text] [Related]
2. Acetylation control of cardiac fatty acid β-oxidation and energy metabolism in obesity, diabetes, and heart failure.
Fukushima A; Lopaschuk GD
Biochim Biophys Acta; 2016 Dec; 1862(12):2211-2220. PubMed ID: 27479696
[TBL] [Abstract][Full Text] [Related]
3. Cardiac Energy Metabolism in Heart Failure.
Lopaschuk GD; Karwi QG; Tian R; Wende AR; Abel ED
Circ Res; 2021 May; 128(10):1487-1513. PubMed ID: 33983836
[TBL] [Abstract][Full Text] [Related]
4. Cardiac fatty acid oxidation in heart failure associated with obesity and diabetes.
Fukushima A; Lopaschuk GD
Biochim Biophys Acta; 2016 Oct; 1861(10):1525-34. PubMed ID: 26996746
[TBL] [Abstract][Full Text] [Related]
5. Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy.
Fillmore N; Mori J; Lopaschuk GD
Br J Pharmacol; 2014 Apr; 171(8):2080-90. PubMed ID: 24147975
[TBL] [Abstract][Full Text] [Related]
6. Mitochondrial dysfunction in diabetic cardiomyopathy.
Duncan JG
Biochim Biophys Acta; 2011 Jul; 1813(7):1351-9. PubMed ID: 21256163
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms of cardiac pathology in diabetes - Experimental insights.
Varma U; Koutsifeli P; Benson VL; Mellor KM; Delbridge LMD
Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt B):1949-1959. PubMed ID: 29109032
[TBL] [Abstract][Full Text] [Related]
8. The Contribution of Cardiac Fatty Acid Oxidation to Diabetic Cardiomyopathy Severity.
Karwi QG; Sun Q; Lopaschuk GD
Cells; 2021 Nov; 10(11):. PubMed ID: 34831481
[TBL] [Abstract][Full Text] [Related]
9. Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus.
Nakamura K; Miyoshi T; Yoshida M; Akagi S; Saito Y; Ejiri K; Matsuo N; Ichikawa K; Iwasaki K; Naito T; Namba Y; Yoshida M; Sugiyama H; Ito H
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408946
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of cardiac dysfunction in diabetic cardiomyopathy: molecular abnormalities and phenotypical variants.
Prandi FR; Evangelista I; Sergi D; Palazzuoli A; Romeo F
Heart Fail Rev; 2023 May; 28(3):597-606. PubMed ID: 35001338
[TBL] [Abstract][Full Text] [Related]
11. Lipid metabolism and its implications for type 1 diabetes-associated cardiomyopathy.
Ritchie RH; Zerenturk EJ; Prakoso D; Calkin AC
J Mol Endocrinol; 2017 May; 58(4):R225-R240. PubMed ID: 28373293
[TBL] [Abstract][Full Text] [Related]
12. An overview of the crosstalk between inflammatory processes and metabolic dysregulation during diabetic cardiomyopathy.
Palomer X; Salvadó L; Barroso E; Vázquez-Carrera M
Int J Cardiol; 2013 Oct; 168(4):3160-72. PubMed ID: 23932046
[TBL] [Abstract][Full Text] [Related]
13. Metabolic abnormalities in the diabetic heart.
Lopaschuk GD
Heart Fail Rev; 2002 Apr; 7(2):149-59. PubMed ID: 11988639
[TBL] [Abstract][Full Text] [Related]
14. Diabetic db/db mice do not develop heart failure upon pressure overload: a longitudinal in vivo PET, MRI, and MRS study on cardiac metabolic, structural, and functional adaptations.
Abdurrachim D; Nabben M; Hoerr V; Kuhlmann MT; Bovenkamp P; Ciapaite J; Geraets IME; Coumans W; Luiken JJFP; Glatz JFC; Schäfers M; Nicolay K; Faber C; Hermann S; Prompers JJ
Cardiovasc Res; 2017 Aug; 113(10):1148-1160. PubMed ID: 28549111
[TBL] [Abstract][Full Text] [Related]
15. Role of Oxidative Stress in Metabolic and Subcellular Abnormalities in Diabetic Cardiomyopathy.
Dhalla NS; Shah AK; Tappia PS
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244448
[TBL] [Abstract][Full Text] [Related]
16. Heart failure and diabetes: role of ATM.
Wingard MC; Frasier CR; Singh M; Singh K
Curr Opin Pharmacol; 2020 Oct; 54():27-35. PubMed ID: 32745970
[TBL] [Abstract][Full Text] [Related]
17. Cardiomyopathy in obesity, insulin resistance and diabetes.
Nakamura M; Sadoshima J
J Physiol; 2020 Jul; 598(14):2977-2993. PubMed ID: 30869158
[TBL] [Abstract][Full Text] [Related]
18. Metabolic abnormalities of the heart in type II diabetes.
Amaral N; Okonko DO
Diab Vasc Dis Res; 2015 Jul; 12(4):239-48. PubMed ID: 25941161
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of sarcolemmal FAT/CD36 by sulfo-N-succinimidyl oleate rapidly corrects metabolism and restores function in the diabetic heart following hypoxia/reoxygenation.
Mansor LS; Sousa Fialho MDL; Yea G; Coumans WA; West JA; Kerr M; Carr CA; Luiken JJFP; Glatz JFC; Evans RD; Griffin JL; Tyler DJ; Clarke K; Heather LC
Cardiovasc Res; 2017 Jun; 113(7):737-748. PubMed ID: 28419197
[TBL] [Abstract][Full Text] [Related]
20. Altered mitochondrial metabolism in the insulin-resistant heart.
Makrecka-Kuka M; Liepinsh E; Murray AJ; Lemieux H; Dambrova M; Tepp K; Puurand M; Käämbre T; Han WH; de Goede P; O'Brien KA; Turan B; Tuncay E; Olgar Y; Rolo AP; Palmeira CM; Boardman NT; Wüst RCI; Larsen TS
Acta Physiol (Oxf); 2020 Mar; 228(3):e13430. PubMed ID: 31840389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
